Racura Oncology Raises $34.3m for Oncology Trials
Key points
- Racura raised $34.3m for three clinical trials
- Funds will support trials in AML, EGFRm lung cancer, and cardioprotection
- No broker or underwriter fees were paid in the raisings
Full summary
Racura Oncology Ltd is pleased to announce it has raised a total of $34.3 million to fund three clinical trials. These funds will support RC220 clinical programs in Acute Myeloid Leukaemia (AML), Epidermal Growth Factor Receptor mutant (EGFRm) non-small cell lung cancer, and anthracycline cardioprotection in solid tumour patients. The funds also provide general working capital. The company has raised the money through Bonus and Piggyback Option conversions, private placements, and Option underwriting without paying broker or underwriter fees.
Guidance
Racura has raised $34.3 million to fund clinical trials and working capital.
Outlook
Racura plans to update investors on the clinical progress of RC220 in the coming months.
Summary generated by a large language model. Please interpret with care.